2,6,8,9Tetrasubstituted Purines as New CDK1 Inhibitors

2,6,8,9Tetrasubstituted Purines as New CDK1 Inhibitors,10.1016/S0960-894X(03)00632-2,Bioorganic & Medicinal Chemistry Letters,Jiřı́ Moravec,Vladimı́r

2,6,8,9Tetrasubstituted Purines as New CDK1 Inhibitors   (Citations: 4)
BibTex | RIS | RefWorks Download
Purine inhibitors of cyclin-dependent kinases attract attention as potential anticancer drugs because their first representative roscovitine recently entered clinical trials. Although well described in terms of structure–activity relationships, we still present here a novel modification of the purine scaffold influencing their inhibitory properties. The introduced C-8 substituents, however, lowered the CDK inhibitory activity of roscovitine, whereas the antiproliferative potential of several derivatives remained high.
Journal: Bioorganic & Medicinal Chemistry Letters - BIOORG MEDICINAL CHEM LETTER , vol. 13, no. 18, pp. 2993-2996, 2003
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
Sort by: